DKSC (Dakshidin) FCF Margin %: 0.00% (As of Sep. 2023)


What is Dakshidin FCF Margin %?

Dakshidin DKSC +33.33% FCF Margin % is 0.00% as of Sep. 2023.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Dakshidin's Free Cash Flow for the three months ended in Sep. 2023 was $0.00 Mil. Dakshidin's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Dakshidin's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, Dakshidin's current FCF Yield % is 0.00%.

The historical rank and industry rank for Dakshidin's FCF Margin % or its related term are showing as below:


DKSC's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.445
* Ranked among companies with meaningful FCF Margin % only.

Dakshidin FCF Margin % Related Terms

Dakshidin FCF Margin % Historical Data

* Premium members only.

The historical data trend for Dakshidin's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dakshidin FCF Margin % Chart

Dakshidin Annual Data
Trend
FCF Margin %

Dakshidin Quarterly Data
Mar19 Mar20 Sep22 Sep23
FCF Margin % 0.00 0.00 0.00 0.00

DKSC vs ECEZ, AFBG, CESX: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dakshidin's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dakshidin FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dakshidin's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Dakshidin's FCF Margin % falls into.


Dakshidin FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Dakshidin's FCF Margin for the fiscal year that ended in . 20 is calculated as

FCF Margin=Free Cash Flow (A: . 20 )/Revenue (A: . 20 )
=/
= %

Dakshidin's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Dakshidin (DKSC) has a FCF Margin % of 0.00% as of Sep. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Dakshidin and its competitors.
Is Dakshidin's FCF Margin % too high?
Dakshidin's current FCF Margin % is 0.00%.
How does Dakshidin's FCF Margin % compare to ECEZ and AFBG?
Dakshidin's FCF Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Dakshidin and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dakshidin's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dakshidin stock overvalued right now?
Dakshidin (DKSC) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Dakshidin (DKSC), the current FCF Margin % is 0.00% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dakshidin Business Description

Address 508 Locust Street, Lockport, NY, USA, 14094
Dakshidin Corp is a Cannabis-based medical product company. The company operates through its online e-commerce store laughingfrogs.com. The company is composed of four synergistic entities: Laughing Frogs, an online sales portal for the company's CBD products; Laughing Frogs Nutraceutical the online sales portal for all non-CBD hemp oil products and its proprietary nutraceutical products, company's new PPE division and Runnymede Farms, a company that is focused on the cultivation of specifically grown Hemp plants. through its growing operations and Joint Ventures with established growers.